CY1119637T1 - Θερμοσχηματιζομενη, ανθεκτικη σε αλλοιωση φαρμακευτικη μορφη δοσολογιας που περιεχει ψευδαργυρο - Google Patents

Θερμοσχηματιζομενη, ανθεκτικη σε αλλοιωση φαρμακευτικη μορφη δοσολογιας που περιεχει ψευδαργυρο

Info

Publication number
CY1119637T1
CY1119637T1 CY20171101265T CY171101265T CY1119637T1 CY 1119637 T1 CY1119637 T1 CY 1119637T1 CY 20171101265 T CY20171101265 T CY 20171101265T CY 171101265 T CY171101265 T CY 171101265T CY 1119637 T1 CY1119637 T1 CY 1119637T1
Authority
CY
Cyprus
Prior art keywords
zinc
thermochemized
dosage contained
medicinal form
distributed
Prior art date
Application number
CY20171101265T
Other languages
Greek (el)
English (en)
Inventor
Lutz Barnscheid
Eric Galia
Anja Geissler
Jana Pätz
Sebastian Schwier
Julia BARONSKY-PROBST
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1119637T1 publication Critical patent/CY1119637T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CY20171101265T 2012-05-11 2017-12-04 Θερμοσχηματιζομενη, ανθεκτικη σε αλλοιωση φαρμακευτικη μορφη δοσολογιας που περιεχει ψευδαργυρο CY1119637T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12003743 2012-05-11
PCT/EP2013/059728 WO2013167735A1 (en) 2012-05-11 2013-05-10 Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP13721766.7A EP2846835B1 (en) 2012-05-11 2013-05-10 Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc

Publications (1)

Publication Number Publication Date
CY1119637T1 true CY1119637T1 (el) 2018-04-04

Family

ID=48407572

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101265T CY1119637T1 (el) 2012-05-11 2017-12-04 Θερμοσχηματιζομενη, ανθεκτικη σε αλλοιωση φαρμακευτικη μορφη δοσολογιας που περιεχει ψευδαργυρο

Country Status (21)

Country Link
EP (1) EP2846835B1 (enExample)
JP (2) JP2015516406A (enExample)
CN (1) CN104428002B (enExample)
AU (1) AU2013257943B2 (enExample)
BR (1) BR112014026768A2 (enExample)
CA (1) CA2870012A1 (enExample)
CY (1) CY1119637T1 (enExample)
DK (1) DK2846835T3 (enExample)
EA (1) EA029171B1 (enExample)
ES (1) ES2650945T3 (enExample)
HR (1) HRP20171718T1 (enExample)
HU (1) HUE035123T2 (enExample)
IL (1) IL234815A0 (enExample)
LT (1) LT2846835T (enExample)
MX (1) MX357783B (enExample)
NO (1) NO2846835T3 (enExample)
PL (1) PL2846835T3 (enExample)
PT (1) PT2846835T (enExample)
RS (1) RS56685B1 (enExample)
SI (1) SI2846835T1 (enExample)
WO (1) WO2013167735A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
PL2997965T3 (pl) 2009-07-22 2019-06-28 Grünenthal GmbH Odporna na manipulacje postać dawkowania opioidów wrażliwych na utlenianie
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
EP2611426B1 (en) 2010-09-02 2014-06-25 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
ES2487244T3 (es) 2010-09-02 2014-08-20 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende un polímero aniónico
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
HRP20181716T1 (hr) 2012-04-18 2018-12-28 Grünenthal GmbH Farmaceutski oblik doziranja otporan na zlonamjernu uporabu i naglo oslobađanje cjelokupne doze
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
WO2015004245A1 (en) 2013-07-12 2015-01-15 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
JP2018513872A (ja) 2015-04-24 2018-05-31 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 異なる粒子から２種の薬物の急速放出をもたらすタンパレジスタントな固定用量組合せ
WO2016170094A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles
WO2016170093A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
US11234974B2 (en) 2015-05-28 2022-02-01 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US10183018B2 (en) 2015-05-28 2019-01-22 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
AU7077287A (en) 1986-03-31 1987-10-08 Union Carbide Corporation Alkylene oxide polymerisation catalyst
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
US4667013A (en) 1986-05-02 1987-05-19 Union Carbide Corporation Process for alkylene oxide polymerization
JP3073054B2 (ja) 1991-07-11 2000-08-07 住友精化株式会社 アルキレンオキシド重合体の製造方法
JP2002265592A (ja) 2001-03-07 2002-09-18 Sumitomo Seika Chem Co Ltd アルキレンオキシド重合体の製造方法
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
DE60224293T2 (de) 2001-09-21 2008-12-11 Egalet A/S Feste dispersionen mit kontrollierter freisetzung von carvedilol
US7300668B2 (en) 2001-10-29 2007-11-27 Massachusetts Institute Of Technology System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
ES2407143T3 (es) 2003-08-06 2013-06-11 Grünenthal GmbH Forma de dosificación protegida contra un posible abuso
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
PL1740156T3 (pl) 2004-04-22 2011-12-30 Gruenenthal Gmbh Sposób wytwarzania zabezpieczonej przed nadużyciem, stałej postaci aplikacyjnej
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
PL1765298T3 (pl) 2004-07-01 2013-01-31 Gruenenthal Gmbh Sposób wytwarzania stałej postaci dawkowania, która jest zabezpieczona przez nadużywaniem, wykorzystujący wytłaczarkę z przekładnią planetarną
WO2006002884A1 (de) 2004-07-01 2006-01-12 Grünenthal GmbH Gegen missbrauch gesicherte, orale darreichtungsform
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CA2572352A1 (en) 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2006133733A1 (en) * 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
AU2008207200B2 (en) 2007-01-16 2011-02-17 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
JP2012508773A (ja) 2008-11-14 2012-04-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 低いｐＨでの難水溶性のイオン化活性薬剤の制御放出のための固体組成物およびその使用方法
PL2997965T3 (pl) * 2009-07-22 2019-06-28 Grünenthal GmbH Odporna na manipulacje postać dawkowania opioidów wrażliwych na utlenianie

Also Published As

Publication number Publication date
RS56685B1 (sr) 2018-03-30
EP2846835B1 (en) 2017-09-06
ES2650945T3 (es) 2018-01-23
PT2846835T (pt) 2017-12-15
EP2846835A1 (en) 2015-03-18
DK2846835T3 (en) 2017-12-04
LT2846835T (lt) 2017-12-27
SI2846835T1 (en) 2018-01-31
JP6541748B2 (ja) 2019-07-10
JP2015516406A (ja) 2015-06-11
CN104428002A (zh) 2015-03-18
EA201401240A1 (ru) 2015-04-30
HUE035123T2 (en) 2018-05-02
JP2018065810A (ja) 2018-04-26
HRP20171718T1 (hr) 2017-12-29
AU2013257943B2 (en) 2017-10-05
CN104428002B (zh) 2017-08-11
WO2013167735A1 (en) 2013-11-14
AU2013257943A1 (en) 2014-10-09
CA2870012A1 (en) 2013-11-14
BR112014026768A2 (pt) 2017-06-27
PL2846835T3 (pl) 2018-02-28
NO2846835T3 (enExample) 2018-02-03
EA029171B1 (ru) 2018-02-28
MX357783B (es) 2018-07-25
IL234815A0 (en) 2014-12-31
HK1207978A1 (en) 2016-02-19
MX2014013095A (es) 2014-12-08

Similar Documents

Publication Publication Date Title
CY1119637T1 (el) Θερμοσχηματιζομενη, ανθεκτικη σε αλλοιωση φαρμακευτικη μορφη δοσολογιας που περιεχει ψευδαργυρο
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1123571T1 (el) Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
AR096439A1 (es) Forma de dosificación resistente al uso indebido que contiene una o más partículas
CY1116100T1 (el) Παραγωγα πυριμιδινονης, η παρασκευη τους και η φαρμακευτικη τους χρηση
CY1123189T1 (el) Αντιμικροβiακο πεπτιδιο
CY1123195T1 (el) Ενεσιμη φαρμακοτεχνiκη μορφη
MA34019B1 (fr) Aryltriazolone liée à un bis-aryle et son utilisation
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
HUE061596T2 (hu) Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
BR112015001371A8 (pt) Composição farmacêutica ou nutracêutica resistente ao suco gástrico com resistência contra a influência de etanol
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
CY1118774T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
CY1118099T1 (el) Δισκια οξεικης ουλιπρισταλης
CY1119151T1 (el) Ν-(4-(αζαϊνδαζολ-6-υλ)-φαινυλ)-σουλφοναμιδiα και η χρηση τους ως φαρμακα
CY1121881T1 (el) Φαρμακοτεχνικη μορφη που περιεχει σταθερη αναλογια ινσουλινης glargine/λιξισενατιδης
CY1120008T1 (el) Βενζαμιδια
CL2012002716A1 (es) Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica.
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
CL2014002822A1 (es) Compuestos derivados de acido oxabiciclo-[2.2.2]-sustituido acetico, inhibidores de dgat1; composicion farmaceutica; combinacion farmaceutica; uso para la prevencion, demora del progreso o el tratamiento del virus de hepatitis c, diabetes tipo ii, sindrome de quilomicrenia, sindrome de quilomicrenia familiar e hiperlipoproteinemia tipo v.
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.